Last reviewed · How we verify

E. Coli Joint Infection — Treatment Landscape & Competitive Intelligence

E. Coli Joint Infection (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating E. Coli Joint Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Rocephin ceftriaxone Generic (originally Roche) Cephalosporin antibiotic (third-generation) Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A 1984-12-21
Ceftriaxon Ceftriaxon Centre Hospitalier Universitaire Vaudois Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Centre Hospitalier Universitaire Vaudois · 1 drug in E. Coli Joint Infection
  2. Generic (originally Roche) · 1 drug in E. Coli Joint Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in E. Coli Joint Infection:

Cite this brief

Drug Landscape (2026). E. Coli Joint Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-joint-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing